Introducing a new global community in acute lymphoblastic leukemia: Know ALL

Know ALL is a global education and awareness initiative that focuses solely on acute lymphoblastic leukemia (ALL) with the aim to provide patients and caregivers with the information, resources, and support to deal with ALL.

Know ALL was founded in 2022. It is a collaboration between Scientific Education Support (SES) and the Acute Leukemia Advocates Network (ALAN).

ALAN is a global network of patient advocates, who are collaborating with SES on Know ALL to ensure that the ALL community has access to the latest information and resources, providing the best possible support and care for patients with ALL and their families.

“Disease awareness, education and information plays a crucial role in ensuring earlier diagnosis, earlier treatment, and better overall outcomes for patients. This is why Know ALL is so important. ALAN is proud to be collaborating with a wide range of stakeholders on Know ALL.” Zack Pemberton-Whiteley, Chair of ALAN and Co-Chair of Know ALL.

Know ALL is guided by a highly experienced global ambassador group who meet regularly to ensure the voice of patients and their families is at the core of the initiative.

“Know ALL is an initiative using the voices of patients with ALL to benefit all those in the ALL community, through spreading awareness, knowledge, and support for all who have a life-changing diagnosis.

Know ALL is important because all cancers should have individual representation. The Know ALL initiative will provide the space for both current, past, and future patients with ALL to access high-quality information about their cancer, both from each other and from experts.

I’m proud of Know ALL because it provides visibility for a not often spoken about cancer, and it is something using the voices of the people ALL affects to build resources that patients with ALL will find useful.” Jaymz Goodman, a patient in remission from ALL and a Know ALL ambassador.

Jaymz Goodman joins the Know ALL initiative with a caregiver and co-chair, Rebekah Hays (US); a patient in remission, Anne-Pierre Pickaert (FR); six patient advocates and co-chair, Zack Pemberton-Whiteley (ALAN, global), Yolima Méndez Camacho (Fundación Colombiana de Leucemia y Linfoma, CO), Amanda Shlosberg (CancerCare, US), Mirjana Babamova (HEMA, Macedonia), Sharon Cohen (Leukemia and Lymphoma Society, US), and Yusuf Adelabu (The White Cell Foundation, NG); and four healthcare professionals, Anthony Moorman (Newcastle University, UK), Charles Mullighan (St. Jude Children's Research Hospital, US), Yervand Hakobyan (Armenian Hematology Association, Armenia), and Jan Cools, (KU Leuven, BE).

Working in collaboration with ALAN and the ambassador group, the Know ALL initiative is delivered by SES, who love nothing more than building communities and networks to facilitate education through collaboration, ensuring that patients have access to the latest support and treatment options.

Know ALL owes thanks to the support of its founding industry partners, Amgen and Jazz Pharmaceuticals, without whom the initiative would not be possible.

For more information on Know ALL, please visit know-alleukemia.com.

For media enquiries or to explore collaboration opportunities, please contact